-ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS disorder, in the second half of 2019
-Neuren retains all rights to trofinetide outside of North America
-Neuren to receive US $10 million upfront plus potential milestones of up to US $455 million and royalties
- Forums
- ASX - By Stock
- NEU
- Ann: Neuren and ACADIA announce agreement for North America
Ann: Neuren and ACADIA announce agreement for North America, page-3
-
- There are more pages in this discussion • 494 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.81 |
Change
-0.160(0.80%) |
Mkt cap ! $2.523B |
Open | High | Low | Value | Volume |
$19.96 | $19.96 | $19.69 | $2.862M | 144.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 317 | $19.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.82 | 389 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 1018 | 19.820 |
4 | 94 | 19.810 |
7 | 252 | 19.800 |
5 | 242 | 19.790 |
3 | 207 | 19.780 |
Price($) | Vol. | No. |
---|---|---|
19.830 | 46 | 6 |
19.840 | 752 | 6 |
19.850 | 916 | 5 |
19.860 | 504 | 7 |
19.870 | 2057 | 3 |
Last trade - 15.15pm 05/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |